A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [(14)C]-ixazomib containing ~500 nCi total radioactivity (TRA), fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Zhang, Steven, Pusalkar, Sandeepraj, Plesescu, Mihaela, Chowdhury, Swapan, Hanley, Michael J., Wang, Bingxia, Xia, Cindy, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Shepard, Dale R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948259/
https://www.ncbi.nlm.nih.gov/pubmed/28932928
http://dx.doi.org/10.1007/s10637-017-0509-1

Ejemplares similares

Ejemplares similares